Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung Biologics (207940) – iM Securities | Annual Operating Profit Surpasses KRW 2T · Pure-CDMO Transition · Three-Pillar Growth Strategy / 2026-01-22 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Legacy Memory Pricing · Earnings Upgrades · Volume Growth / 2026-03-03 Research
  • [Research] LIG D&A (079550) – Hanwha Investment & Securities | 3Q25 Review · Secured Growth Materialization · Expanding Export Share / 2025-11-07 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | LTA · Capex Discipline · Cycle Stability / 2026-01-28 Research
  • [Research] Samsung SDI (006400) – Mirae Asset | North American ESS · European LFP Orders · Market Share Expansion / 2026-08-13 Research
  • [IR] SK hynix (000660 / SKHY) – Q1 2024 Earnings Presentation / 2024-04-25 IR Room
  • [Research] Alteogen (196170) – Hana Securities | ALT-B4 Differentiation Potential · Enhanze Biosimilar Concerns Dispelled · Qlex Revenue Visibility / 2026-07-15 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | Supply Tightness · LTA · Shareholder Returns / 2026-07-30 Research

[Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · PHLX Inclusion · Valuation Re-rating / 2026-06-01

Posted on June 1, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Mirae Asset Securities

Analyst : Younggun Kim

Investment Rating : BUY (Maintained)

Target Price : KRW 3,800,000 (Maintained)

Core Momentum : The planned US ADR listing is expected to expand global investor access and create potential passive inflows through PHLX index inclusion, supporting a valuation re-rating that narrows the multiple discount to global semiconductor peers.

📊 1. [Valuation & Key Financial Metrics]

  • Equity Research Date: June 1, 2026
  • Investment Rating: BUY (Maintained) / Target Price: KRW 3,800,000 (Maintained)
  • Current Price (as of 26/5/29): KRW 2,333,000 / Upside Potential: 62.9%
  • Operating Profit (26F, KRW bn): 289,785 / Consensus Operating Profit (26F, KRW bn): 256,000
  • EPS Growth (26F, %): 441.9 / MKT EPS Growth (26F, %): 239.0
  • P/E (26F, x): 7.3 / MKT P/E (26F, x): 9.2 / KOSPI: 8,476.15
  • Market Capitalization (KRW bn): 1,662,735 / Shares Outstanding (mn shares): 713 / Float Ratio (%): 74.9
  • Foreign Ownership (%): 51.4 / Beta (12M) Daily Return: 1.73
  • 52-Week Low / High (KRW): 204,500 / 2,333,000
  • FY 2026F Estimates: Revenue KRW 366,486 bn, Operating Profit KRW 289,785 bn, Net Income KRW 228,203 bn, EPS KRW 319,452, ROE 96.7%, P/E 7.3x, P/B 4.7x, Dividend Yield 0.2%
  • FY 2027F Estimates: Revenue KRW 530,534 bn, Operating Profit KRW 420,470 bn, Net Income KRW 321,079 bn, EPS KRW 450,509, ROE 62.9%, P/E 5.2x, P/B 2.5x, Dividend Yield 0.3%

🚀 2. [Market Opportunities & Business Outlook]

  • The company confidentially submitted a registration statement for an ADR listing public offering to the US SEC on March 24, targeting a listing within the year through a new share issuance method of up to 2.5% (17.9 million shares).
  • Following the ADR listing, inclusion in the Philadelphia Semiconductor Index (PHLX) is anticipated, which could bring passive inflow distributions supported by weight caps on top-tier index constituents.
  • Operating profits for 2Q26 and 26F are estimated at KRW 67 trillion and KRW 290 trillion respectively, outperforming recent 1-month market consensus, while its 27F P/E of 5.2x and P/B of 2.4x highlight absolute undervaluation compared to PHLX averages.
  • Given strict commercial law revisions regarding treasury stock disposals following its full treasury stock cancellation, the ADR issuance is most likely to proceed via new share issuance tailored to maintain the largest shareholder’s stake requirements.

📝 Editor’s Comment (Perspective & Thesis Verification)

The analyst evaluates SK hynix as an enterprise combining solid fundamental earnings growth with dual catalysts: a US ADR listing and expectations of PHLX index inclusion, capturing global passive fund inflows and valuation re-rating. This perspective focuses on closing the multiple discount gap relative to global semiconductor peers despite its robust earnings power.

To determine whether this investment thesis is actively unfolding, key monitoring items include tracking the progress of the US ADR public offering timeline and the finalization of new share issuance scale within the year. In addition, it is necessary to verify post-listing daily trading volume requirement of at least 1.5 million shares after 6 months of listing and monitor the visibility of PHLX index inclusion and passive inflow distribution during upcoming periodic rebalancings such as September 2027. These developments can be tracked through corporate earnings releases, official IR materials, and regulatory filings on DART/SEC.

📢 Disclaimer & Source Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports. Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor. Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Mirae Asset | LTA · HBM Demand · Valuation Re-rating / 2026-05-27
Next Post: [Research] Alteogen (196170) – Daishin Securities | Key US Patent Risks Significantly Eased · New Licensing Catalysts · Keytruda SC Milestones / 2026-06-02

Related Posts

  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Enterprise SSD · NAND Pricing · Profitability / 2026-05-18 Research
  • [Research] LIG D&A (079550) – Daishin Securities | 1Q26 Review · Earnings Surprise · Export Diversification / 2026-05-08 Research
  • [Research] SK hynix (000660 / SKHY) – Hanwha | LTA · HBM · Earnings Sustainability / 2026-04-24 Research
  • [Research] Samsung Biologics (207940) – IBK Securities | Plant 5 PPQ Revenue · US Site Consolidation · Guidance Revision Potential / 2026-04-23 Research
  • [Research] Samsung SDI (006400) – Hanwha Investment & Securities | Delayed EV Recovery · ESS Highlights as Sole Driver · Target Price Cut / 2026-01-07 Research
  • [Research] LigaChem Biosciences (141080) – Kyobo Securities | Pipeline Clinical Progress · IND Filings · Tech Transfer / 2026-04-01 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing · Operating Leverage · Shareholder Returns / 2026-01-30 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Enterprise SSD · NAND Pricing · Profitability / 2026-05-18 Research
  • [Research] SK hynix (000660 / SKHY) – Yuanta | Memory Pricing · Long-Term Contracts · Earnings Stability / 2026-04-23 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Supply Discipline · LTA · Shareholder Returns / 2026-07-30 Research
  • [Research] Celltrion (068270) – IBK Securities | New Biosimilar Mix Expansion · Operating Leverage · H2 Margin Expansion / 2026-05-07 Research
  • [Research] LIG D&A (079550) – Yuanta Securities | Cheongung-II Demand Surge · OPM Guidance Upgrade · Middle East Overlap / 2026-08-07 Research
  • [Research] Samsung SDI (006400) – Hana Securities | SDC Stake Monetization Pursuit · Up to KRW 11T Liquidity · Valuation Multiples Re-rating / 2026-02-20 Research
  • [Research] Samsung SDI (006400) – DS Investment & Securities | 4Q Turnaround Visibility · Non-PFE LFP ESS · European Volume Models / 2026-04-29 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme